ESMO 2019 | TROPHY-U-01: Initial findings
Scott Tagawa
Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial results from the TROPHY-U-01 phase II trial, assessing the efficacy and toxicities in the first cohort of patients (those who have already received platinum-based chemotherapy and immune checkpoint based therapy) with sacituzumab govitecan. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Similar topics
Related videos

Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles

Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa

Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen

Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges

NIVOREN GETUG-AFU 26: Updates and implications
Laurence Albiges
29th September 2019
More from Scott Tagawa